A Study of FOCAL Pulsed Field Ablation With the TactiFLEX SE Catheter and Volt Generator for the Treatment of Paroxysmal Atrial Fibrillation (FOCALFLEX)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 48
- 主要终点
- Freedom from documented AF/AFL/AT recurrence
研究概览
简要总结
This clinical investigation is intended to demonstrate safety and effectiveness of the TactiFlex™ Ablation Catheter Sensor Enabled™, the Volt™ Pulse Field Ablation (PFA) Generator, and EnSite™ X EP System with EnSite™ Pulsed Field Ablation Software for the treatment of symptomatic, recurrent paroxysmal atrial fibrillation (PAF).
详细描述
This is a pre-market, prospective, single-arm, non-randomized, multicenter clinical investigation. Up to 150 subjects will be enrolled in this clinical investigation at up to 25 investigational sites worldwide. The clinical investigation is sponsored by Abbott.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented symptomatic paroxysmal AF (PAF). Documentation requirements are as follows:
- •Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 6 months prior to enrollment AND
- •One electrocardiographically documented PAF episode within 12 months prior to enrollment.
- •Plans to undergo a catheter ablation procedure due to symptomatic PAF
- •At least 18 years of age
- •Able and willing to comply with all trial requirements including pre-procedure, post- procedure, and follow-up testing and requirements
- •Informed of the nature of the trial, agreed to its provisions, and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.
排除标准
- •Previously diagnosed persistent or long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)
- •Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures in the preceding 90 days
- •Known presence of cardiac thrombus
- •Left atrial diameter (LAD) ≥ 5.5 cm (anteroposterior diameter) within 180 days prior to the index procedure
- •Left ventricular ejection fraction (LVEF) < 35% as assessed with echocardiography or computerized tomography (CT) within 180 days prior to the index procedure
- •New York Heart Association (NYHA) class III or IV heart failure
- •Body mass index > 40 kg/m2
- •Pregnant or nursing
- •Patients who have had a ventriculotomy or atriotomy within the preceding 28 days of procedure
- •Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days
- •Stroke or TIA (transient ischemic attack) within the last 90 days
- •Heart disease in which corrective surgery is anticipated within 180 days after procedure
- •History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant state
- •Contraindication to long term anti-thromboembolic therapy
- •Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
- •Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
- •Previous left atrial surgical or left atrial catheter ablation procedure (including left atrial appendage (LAA) closure device)
- •Plans to have an LAA closure device implanted during the follow-up period
- •Presence of any condition that precludes appropriate vascular access
- •Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
- •Previous tricuspid or mitral valve replacement or repair
- •Patients with prosthetic valves
- •Patients with a myxoma
- •Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt
- •Stent, constriction, or stenosis in a pulmonary vein
- •Rheumatic heart disease
- •Hypertrophic cardiomyopathy
- •Active systemic infection
- •Renal failure requiring dialysis
- •Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- •Presence of an implantable therapeutic cardiac device including permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) or planned implant of such a device for any time during the follow-up period. Presence of an implantable loop recorder is acceptable as long as it is removed prior to insertion of the investigational device.
- •Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from this study Sponsor
- •Unlikely to survive the protocol follow up period of 12 months
- •Presence of other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- •Individuals without legal authority
- •Individuals unable to read or write
研究组 & 干预措施
treatment arm
Patients treated for paroxysmal atrial fibrillation with the TactiFlex™ Ablation Catheter Sensor Enabled™ (SE).
干预措施: TactiFlex™ Ablation Catheter Sensor Enabled™ (Device)
结局指标
主要结局
Freedom from documented AF/AFL/AT recurrence
时间窗: 6 months
The primary effectiveness endpoint for this clinical trial is freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of \>30 seconds duration that are documented by protocol-specified 12-lead ECG, TTM or Holter monitor (HM) devices after the index ablation procedure through 6 months of follow-up (after a 90-day blanking period following the index ablation procedure).
Incidence of primary safety endpoint events
时间窗: 7 days
The primary safety endpoint is the proportion of subjects experiencing a device and/or procedure-related serious adverse event (SAE) with onset within 7 days of any ablation procedure (index or repeat procedure performed 0-90 days post initial procedure) that uses the TactiFlex PFA System defined below: * Atrio-esophageal fistula * Cardiac tamponade/perforation * Death * Heart block * Myocardial infarction * Pericarditis * Phrenic nerve injury resulting in diaphragmatic paralysis * Pulmonary edema * Pulmonary vein stenosis * Stroke/cerebrovascular accident * Thromboembolism * Transient ischemic attack * Vagal nerve injury/gastroparesis * Major Vascular access complications / major bleeding event * Device and/or procedure related cardiovascular and/or pulmonary adverse event that prolongs hospitalization for more than 48 hours (excluding hospitalization solely for arrhythmia recurrence or non-urgent cardioversion)
次要结局
未报告次要终点